Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials

Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials

Abstract Introduction This integrated analysis of the phase 2/3 and phase 3 SELECT trials describes the safety profile of upadacitinib, an oral Janus kinase inhibitor, for up to 5 years of exposure across psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarth...

Full description

Bibliographic Details
Main Authors: Gerd R. Burmester, Jayne Stigler, Andrea Rubbert-Roth, Yoshiya Tanaka, Valderilio F. Azevedo, Derek Coombs, Ivan Lagunes, Ralph Lippe, Peter Wung, Lianne S. Gensler
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-04-01
Series:Rheumatology and Therapy
Subjects:
Adalimumab
Ankylosing spondylitis
JAK inhibitor
Non-radiographic axial spondyloarthritis
Psoriatic arthritis
Safety
Online Access:https://doi.org/10.1007/s40744-024-00671-4

Internet

https://doi.org/10.1007/s40744-024-00671-4

Similar Items